IAMBIC

Market position

A bespoke, AI-driven custom footwear brand positioned at the intersection of consumer footwear and health/biomechanics, with recognition including a TIME Best Invention of the Year award, induction into the Miami Shoe Museum alongside Salvatore Ferragamo, and coverage in TIME, Forbes, The Wall Street Journal, Shape, Athletech News, Sourcing Journal and The Harvard Gazette.

Rather than matching customers to existing mass-produced shoes, IAMBIC controls the full stack from smartphone scan to manufacturing, producing an individually shaped last and shoe. Distinguishing elements include 12 patent-pending inventions, NSF and Center for Biotechnology-funded R&D, a scientific advisory relationship with footwear biomechanics researcher Dr. Hylton Menz, manufacturing by master shoemakers in Portugal, HSA/FSA eligibility, and a guarantee of unlimited refits.

Technology

Advanced smartphone 3D scanning paired with computer vision benchmarked against NASA-grade 3D scanning, feeding AI fit prediction models trained on more than 20 biometric variables including foot structure, biomechanics, lifestyle and gait history. The platform generates an AI-tailored last for each shoe from smartphone camera scans, a comfort questionnaire and wear patterns from the customer's previous IAMBIC pair. It comprises 12 patent-pending inventions covering fit prediction, scan processing and last design, plus adaptive molding, closed-loop manufacturing and the Sole Print layered support and dynamic fit platform. The company states 98% fit accuracy and more than 50,000 precision-fit profiles/foot scans used to train the fit engine.

Go-to-market

Online direct sales with app-based self-scanning that lets customers order from anywhere, supplemented by an in-person Executive Experience scanning location in New York City, limited-edition drops such as the Art Gods Series tied to the Miami F1 Grand Prix and a partnership with Motorsport Lab, HSA/FSA payment enablement via Truemed, customer testimonials and extensive earned media.

Consumers who are poorly served by standard sizing systems—Wang estimates shoes fit about 33% of people well and 40% tolerably, leaving 27% without good options—as well as professionals, executives and athletes seeking all-day comfort, and people with chronic foot pain or pressure-point issues.

Geography

Global headquarters and an Executive Experience scanning location in New York City; manufacturing facility and supply chain in Portugal established in 2022; products delivered to customers' doors.

History

IAMBIC was established in 2020 in New York City by Maeve Wang and Dr. Raza Hassan, partnering with Dr. Hylton Menz and building smartphone 3D scanning and AI fit prediction models with eight patent-pending inventions. In 2021 it secured U.S. National Science Foundation funding, expanded from analytics into full-stack footwear design and manufacturing, and developed four further inventions in adaptive molding and closed-loop manufacturing. In 2022 the company created its first AI-powered MODEL T prototype, opened its Portugal facility, launched Sole Print, joined Harvard Innovation Labs, scrapped the earlier app, and raised over $1 million from angel investors. In 2023 the MODEL T was named a TIME Best Invention, the company opened an Executive Experience scanning space in New York City, its debut collection sold out in two weeks, and it earned press coverage in Forbes and The Wall Street Journal. In 2024 it delivered the MODEL T via smartphone scanning, appointed former Puma Global Footwear Director Adrian Gill as Creative Director, was selected for Techstars NYC, expanded government-backed R&D with the Center for Biotechnology and NSF, was a Presidents Innovation Challenge finalist at Harvard, and debuted a limited-edition capsule at the Miami F1 Grand Prix. The company was later selected for the Harvard Alumni Entrepreneurs Accelerator cohort.

Risks & controversies

The company's early smartphone fit app failed to produce accurate matches because product data across the footwear supply chain was inaccurate by three to 20 millimeters, leading the team to abandon the app in 2022 and build its own manufacturing. Its NSF grant had to be re-applied for with a new protocol and feasibility plan. Co-founder Tyson Park died suddenly. HSA/FSA eligibility is subject to independent clinical review and is not guaranteed, and the company's fit-accuracy and profile-count claims are self-reported.